Target lesion failure with biodegradable polymer sirolimus-eluting stents ( 69 cases ; 65 % ) was non-inferior to durable polymer everolimus-eluting stents ( 70 cases ; 66 % ) at 12 months ( absolute risk difference -014 % , upper limit of one-sided 95 % CI 197 % , p for non-inferiority < 00004 ) .